Signal active
Investment Firm
Overview
UCSF scientist over twenty-five (25) years, twenty-three as Director of the Laboratory for Cell Analysis (LCA). Currently Director of the Lab for Advanced Cytometry (LAC) and the Sony Biotechnology Center at UCSF in the Department of Laboratory Medicine.
• Built the LCA into one of the largest academic cytometry core facilities worldwide. • Direct contribution to grants totals well over $40M in extramural funding. • Helped design and build five commercial flow cytometers, two cell sorters, and two commercial confocal microscopes.
Current work supports several developing technology fields including automated digital pathology and laser-based microdissection systems, next generation clinical cell sorters, spectral flow cytometry, chip-based cytometry and point-of-care devices, wide-field high-resolution deep tissue confocal microscopy, mass spec flow cytometry (CyTOF), and spectral in vivo imaging. Application development includes single cell genomics, new functional reporter probes for cell cycle, cellular biosensors, FRET/FRAP/FLIM reporters for monitoring protein and drug interactions, new encoded carrier technology for immune profiling and liquid arrays, and rapid identification systems for virology and microbiology. Hyun also participates in biomedical software and database design, and testing of new algorithms for cytometric data processing and presentation of results.
Highlights
1873
Biotechnology
10001+
2
0
undefined
Early Stage Venture, Late Stage Venture
N/A
Location
United States, North America
Contact Information
Social
Profile Resume
University of California, San Francisco, established in 1873 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture investments across Cloud Computing, Biotechnology, Life Science, Medical, Information Technology, Energy, Health Care, Industrial Automation, Social, Non Profit. Their recent investments include ArsenalBio, Hitachi Ventures, Emerson Collective, Kleiner Perkins, Bristol-Myers Squibb. The highest investment round they participated in was $33.1B. Among their most notable exits are ArsenalBio and Hitachi Ventures. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Employees
Investment portfolio
2
1
0
undefined
Investments
2
Annouced Date | Organization Name | Industry | Money Raised |
---|---|---|---|
Sep 01, 2020 | - | - | 33.5M |
Sep 06, 2022 | ArsenalBio | Cloud Computing | 220.8M |
Exits
0
Funding Timeline
2
9
0
Funding Rounds
2
University of California, San Francisco has raised 2 rounds. Their latest funding was raised on Sep 06, 2022 from a Series B - ArsenalBio round.
Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
---|---|---|---|---|
Sep 01, 2020 | Series C - Hazel Health | - | 33.5M | - |
Sep 06, 2022 | Series B - ArsenalBio | - | 220.8M | - |
Investors
9
University of California, San Francisco is funded by 9 investor(s). Baldrick's Foundation and American Medical Association Kantor are the most recent investors.
Investor Name | Lead Investor | Funding Round | Money Raised |
---|---|---|---|
Department of Cannabis Control | Yes | Grant - University of California, San Francisco | 904.1K |
American Medical Association | Yes | Grant - University of California, San Francisco | 0 |
- | Yes | Grant - University of California, San Francisco | 0 |
Baldrick's Foundation | Yes | Grant - University of California, San Francisco | 0 |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
Annouced Date | Fund Name | Money Raised |
---|---|---|
May 10, 2013 | OTPPLESS | 1.0M |
May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.